The National Eye Institute (NEI) has awarded Microbiotix, Inc. a $674,963 Project Grant (CFDA 93.867 - Vision Research) to advance the development of filociclovir (FCV) for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis. The funding will enable Microbiotix to complete final formulation work, conduct IND-enabling GLP toxicology studies, and confirm efficacy parameters to support an Investigational New Drug (IND) submission to the FDA for the treatment of ocular human adenovirus (HAdV) infections. This project aligns with the NEI's research priority to develop safe and effective treatments for HAdV-related epidemic keratoconjunctivitis, a severe ocular infection that can lead to long-term visual sequelae. The award covers a project period from February 1, 2025, to January 31, 2028.
Generated 2/25/25, 5:04 AM